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We investigated the diagnostic potential of simultaneous 18F-FET PET/MR-imaging for differentiation 
between recurrent glioma and post-treatment related effects (PTRE) using quantitative volumetric 
(3D-VOI) lesion analysis. In this retrospective study, a total of 42 patients including 32 patients with 
histologically proven glioma relapse and 10 patients with PTRE (histopathologic follow-up, n = 4, 
serial imaging follow-up, n = 6) were evaluated regarding recurrence. PET/MR-imaging was semi-
automatically analysed based on FET tracer uptake using conservative SUV thresholding (isocontour 
80%) with emphasis on the metabolically most active regions. Mean (relative) apparent diffusion 
coefficient (ADCmean, rADCmean), standardised-uptake-value (SUV) including target-to-background 
(TBR) ratio were determined. Glioma relapse presented higher ADCmean (MD ± SE, 284 ± 91, p = 0.003) 
and TBRmax (MD ± SE, 1.10 ± 0.45, p = 0.02) values than treatment-related changes. Both ADCmean 
(AUC ± Se = 0.82 ± 0.07, p-value < 0.001) and TBRmax (AUC ± Se = 0.81 ± 0.08, p-value < 0.001) 
achieved reliable diagnostic performance in differentiating glioma recurrence from PTRE. Bivariate 
analysis based on a combination of ADCmean and TBRmax demonstrated highest diagnostic accuracy 
(AUC ± Se = 0.90 ± 0.05, p-value < 0.001), improving clinical (false negative and false positive) 
classification. In conclusion, biparametric analysis using DWI and FET PET, both providing distinct 
information regarding the underlying pathophysiology, presented best diagnostic accuracy and clinical 
benefit in differentiating recurrent glioma from treatment-related changes.
Glioma recurrence after multimodal treatment with surgery and/or radio-/chemotherapy is still common. Early 
detection of relapse and immediate therapy play an important role in clinical follow-up. Neurosurgical biopsy 
is considered the current diagnostic standard, but it involves the hazards of invasive surgical intervention, such 
as neurological deficits, post-operative infection or intracranial haematoma. Thus, there is great interest in the 
development and application of non-invasive diagnostic approaches, potentially reducing the risk of severe side 
effects for patients as well as health care costs. Differentiation between recurrent glioma and post-treatment 
related effects (PTRE), such as pseudoprogression and radionecrosis, can be challenging as both share clini-
cal symptoms and morphological imaging characteristics1,2. Therefore, as a clinical guideline, the Response 
Assessment in Neuro-Oncology (RANO) Working Group published criteria for response evaluation3,4, taking 
more advanced imaging approaches into consideration, such as perfusion magnetic resonance imaging (pMRI), 
magnetic resonance spectroscopy (MRS), single-photon emission computed tomography (SPECT) or positron 
emission tomography (PET). Commonly, however, many of these alternative methods are not established in clin-
ical routine due to their limited clinical availability and considerable complexity. In particular, the 18F-labelled 
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non-natural amino acid 18F-fluoroethyl-L-tyrosine (FET) emerged as a promising PET tracer candidate, target-
ing the tumour metabolism without relevant background signal, favourable half-life and efficient routine tracer 
production5–7. In contrast to long-established tracers in the field of neurooncology, such as 18F-fludeoxyglucose 
(FDG) and 11C-L-methionine (MET), FET was reported to exhibit relatively low uptake in inflammation8,9. In 
the last few years, several studies provided evidence that FET is a useful tracer for diagnosis of primary brain 
tumours, treatment planning and tumour grading7.
In clinical routine, PET tracer uptake evaluation is either performed using qualitative visual assessment, 
which is subjective and dependent on clinical experience, or using semi-quantitative approaches based on 
standardised-uptake-value (SUV). Upon tumour segmentation using a 2D region-of-interest (2D-ROI), which 
is more common, or a 3D volume-of-interest (3D-VOI), which determines tracer uptake in a more robust man-
ner10, quantitative image-derived parameters can be computed from the respective delineation.
Prior to the adoption of hybrid PET/MR-imaging, sequential image acquisition with alignment during 
post-processing was standard practice. However, with the recent development of hybrid PET/MRI, simultane-
ous multimodal imaging was introduced, which combines the informative value of functional and structural 
MR-imaging as well as metabolic PET-imaging with the benefit of high spatial and temporal conformance and 
improved technical correction methods11.
In the current study, we investigated whether differentiation between recurrent glioma and treatment-related 
changes could be improved by simultaneous PET/MR-imaging, including diffusion weighted imaging (DWI) 
and FET PET, using quantitative volumetric (3D-VOI) lesion analysis with emphasis on the metabolically most 
active regions.
patients and Methods
patient collective. Approval from the institutional ethics board (Charité University Hospital Berlin, 
Germany, EA1/175/18) was obtained. The study was performed in accordance with the principles of the Helsinki 
Declaration. In this retrospective study, a total of 42 consecutive patients (PTRE/recurrence, 10/32, female/male, 
18/24, age (M ± SD), 47 ± 13 a, high-/low-grade glioma (HGG/LGG), 40/2, O6-methylguanine DNA meth-
yltransferase (MGMT+/−) mutation, 22/14 (6 unknown), isocitrate dehydrogenase 1 (IDH1+/−) mutation, 
21/18 (3 unknown), loss of heterozygosity on chromosomes 1p and 19q (LOH1p/19q+/−), 10/17 (15 unknown)) 
with hybrid FET PET/MR-imaging (Charité University Hospital Berlin, Germany, 2017–2018) were included, 
as shown in Fig. 1. According to the eligibility criteria, all patients with recurrent glioma presented available 
histopathology, while patients with PTRE either had follow-up with histopathology (n = 4) or conclusive serial 
imaging (n = 6, ≥ 4 MRI follow-up examinations) in accordance to the Response Assessment in Neuro-Oncology 
(RANO) criteria and the conclusion of an interdisciplinary board of clinical experts. Conventional clinical eval-
uation was derived from the final conclusion of the written imaging report. All patients gave written informed 
consent regarding the use of their data.
pet-MR imaging protocols. Simultaneous FET PET/MRI acquisition was performed on MAGNETOM 
Biograph mMR (Siemens Healthcare, Erlangen, Germany; 3 T PET/MRI hybrid, 45 mT/m maximum gradient 
amplitude, 200 T/m/s maximum gradient slew rate, LSO crystal, 4.3 mm average spatial resolution at FWHM at 
1 cm, 15.0 kcps/MBq sensitivity at center, 13.8 kcps/MBq sensitivity at radial offset of 10 cm12). After intravenous 
FET tracer injection (M ± SD, 163 ± 23 MBq; 180 MBq standard-dose for adults with body-weight ≥ 60 kg, indi-
vidual dose is calculated according to a weight scale for body-weight < 60 kg) simultaneous FET PET/MRI acqui-
sition was performed in list-mode for up to 60 minutes. Gadolinium (Gd) contrast administration was applied 
according to the patient’s total body-weight.
PET/MRI examinations included, inter alia, a transversal T1-weighted ultrashort echo time (UTE) sequence 
for attenuation and scatter correction (TR/TE1/TE2 = 4.64/0.07/2.46 ms; flip-angle = 10°; matrix-size = 
192 × 192 × 192; voxel-size = 1.6 × 1.6 × 1.6 mm), PET acquisition, DWI/ep2d-DIFF 3-scan trace (TR/TE = 
10000/101 ms; matrix-size = 230 × 230 × 230; voxel-size = 1.2 × 1.2 × 3.0 mm; thickness = 3 mm; slices = 48; 
Figure 1. Flow diagram illustrating the study selection process. Between 2017 and 2018, we identified 226 
patients, who received hybrid 18F-FET PET/cMRI. According to the eligibility criteria, a total of 42 patients with 
glioma recurrence in question were included into our retrospective study.
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apparent diffusion coefficient (ADC) map; diffusion-scheme = bipolar; diffusion-weighting = 2; b-values = 0 s/
mm2, 1000 s/mm2; echo-spacing = 1.08 ms; EPI-factor = 192; bandwidth = 1002 Hz/Px) and post-contrast T1/
FL2D-TRA (TR/TE = 250/2.66 ms; flip-angle = 70°; matrix-size = 230 × 230 × 230; voxel-size = 0.7 × 0.7 × 5.0 m
m; thickness = 5 mm; slices = 30). PET was sorted into a sinogram, which was reconstructed into transaxial slices 
using an iterative ordered-subset expectation maximisation algorithm (OSEM) with 3 iterations and 21 subsets 
(matrix-size = 344 × 344 × 127; voxel-size = 1.0 × 1.0 × 2.3 mm; zoom = 2; gaussian-filter = 3 mm). Emission data 
were corrected for decay, randoms, dead time, scatter and attenuation.
Volumetric image analysis. Image analysis was performed using OsiriX MD 10. Attenuation corrected 
PET was matched to the respective apparent diffusion coefficient (ADC) map. Using conservative SUV threshold-
ing (isocontour 80%, IC80; threshold determined in a pilot experiment) with emphasis on the metabolically most 
active regions, a volume-of-interest (3D-VOI) was semi-automatically delineated based on attenuation-corrected 
PET. Mean background signal was computed from a contralateral 2D-ROI with similar size (unaffected brain 
tissue including grey and white matter) on a representative slice (slice with highest mean uptake within the 
3D-VOI), as an adaptation of recommendations from the German guideline13. Where more than one lesion was 
apparent, the most prominent lesion (greatest lesion size, contrast-enhancement and PET tracer uptake, closest 
to the resection cavity or primary tumour location) was analysed.
Apparent diffusion coefficients (all reported values in 10−6 mm2/s) were determined using the same 3D-VOI 
based on high tracer uptake upon marginal adaptation to avoid overlap with resection cavity or cerebrospinal 
fluid space. Relative apparent diffusion coefficient (rADC) and target-to-background (TBR) ratio were calcu-
lated from standardised-uptake-value (SUVmean, SUVmax) or apparent diffusion coefficient (ADCmean) and 
the unaffected contralateral background signal (ratio of lesion signal and contralateral mean background signal).
Statistical analysis. Receiver Operating Characteristic (ROC) curves were computed with respective Area 
Under the Curve (AUC), p-value, sensitivity and specificity. Youden’s index was determined to find the best 
cut-off point (independent from prevalence). ROC curves from univariate and bivariate analysis were compared 
for differences using a non-parametric approach. Biparametric analysis was performed in a step-wise approach 
(each parameter was evaluated separately, one parameter above threshold was classified as recurrence) using a 
binary model. Comparative analysis between recurrence (REC) and post-treatment-related (PTRE) groups were 
performed using independent samples t-tests (reported values show mean and standard error). p-value < 0.05 
was considered statistically significant.
Results
Evaluation of DWI- and FET PET-derived imaging parameters. Recurrent glioma presented higher 
ADCmean (1313 (REC) vs. 1029 (PTRE), MD ± SE, 284 ± 91, p = 0.003), rADCmean (1.72 (REC) vs. 1.37 
(PTRE), MD ± SE, 0.349 ± 0.125, p = 0.008), TBR80mean (2.75 (REC) vs. 1.80 (PTRE), MD ± SE, 0.95 ± 0.38, 
p = 0.02) and TBRmax (3.18 (REC) vs. 2.09 (PTRE), MD ± SE, 1.10 ± 0.45, p = 0.02) values than post-treatment 
related effects, as shown in Fig. 2.
Due to conservative SUV thresholding with emphasis on regions with highest metabolic activity, mean and 
maximum SUV demonstrated high positive correlation for both recurrent glioma (R = 0.999, 95%-CI = 0.997–
0.999, p < 0.001) and post-treatment related effects (R = 0.999, 95%-CI = 0.999–1.000, p < 0.001) groups.
No statistically significant association was apparent for SUV (0.94 (REC) vs. 1.11 (PTRE), MD ± SE, 
−0.174 ± 0.107) or ADC (768 (REC) vs. 755 (PTRE), MD ± SE, 13 ± 29) contralateral background signals (see 
Fig. 2).
Diagnostic performance of DWI, FET PET and biparametric analysis. Mean apparent diffusion 
coefficient (AUC ± SE, 0.82 ± 0.07, p-value < 0.001, 95%-CI = 0.666–0.918) presented good diagnostic perfor-
mance with an optimal cut-off at ADCmean > 1254 (62% sensitivity, 100% specificity), as shown in Fig. 3b and 
Table 1.
Maximum target-to-background ratio (AUC ± SE = 0.81 ± 0.08, p-value < 0.001, 95%-CI = 0.660–0.915) 
showed similar diagnostic performance (see Fig. 3a and Table 1) with 81% sensitivity and 60% specificity at the 
clinically established threshold TBRmax > 2.
ADCmean presented additional diagnostic value, when TBRmax was close to the clinically established thresh-
old (TBRmax > 2), effectively improving clinical detection and decision-making, as demonstrated in Fig. 4. Few 
cases showed recurrent glioma, as suggested by increased TBRmax > 2, with considerably lower mean appar-
ent diffusion coefficient (ADCmean < 900), suggesting diffusion restriction due to high tumour cellularity (see 
Fig. 5).
When both DWI- and FET-derived parameters were combined in biparametric approach, the highest accu-
racy (AUC ± SE = 0.90 ± 05, p-value < 0.001, 95%-CI = 0.768–0.971) was achieved (see Fig. 3c). Compared 
to conventional clinical assessment, as shown in Table 1, biparametric analysis with ADCmean > 1254 and 
TBRmax > 2 presented increased sensitivity (97% vs. 91%) and specificity (60% vs. 44%), improving clin-
ical false negative (−6%) and false positive (−16%) classification. However, no statistically significant differ-
ences regarding diagnostic power were observed between bivariate analysis and univariate analysis with either 
TBRmax (difference in AUC ± SE = 0.09 ± 0.05, 95%-CI = −0.00702–0.185, p = 0.07) or ADCmean (difference 
in AUC ± SE = 0.08 ± 0.05; 95%-CI = −0.0197–0.188, p = 0.11).
Benefit of biparametric analysis compared to conventional clinical assessment is demonstrated in Fig. 6, indi-
cating that either surgery could have been prevented or earlier detection could have been achieved. First row 
(see Fig. 6, panel α) demonstrates a patient with a treated WHO III° oligodendroglioma (MGMT+, IDH1+, 
LOH1p/19q+), originally classified as relapse. In concordance with histopathology, TBRmax (TBRmax = 1.82) 
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and ADCmean (ADCmean = 1133) indicated treatment-related changes. Second row (see Fig. 6, panel β) presents 
a patient with a WHO III° astrocytoma (MGMT+, IDH1+, LOH1p/19q−) with an ambiguous report concluding 
that no high-grade recurrence was detected. An MRI follow-up examination (after 4 months) gave rise to the 
suspicion of relapse, which was later histologically proven (5 months after hybrid PET/MRI). While TBRmax was 
close to the threshold (TBRmax = 1.99), ADCmean (ADCmean = 1757) suggested recurrent glioma. Third row 
(see Fig. 6, panel γ) shows recurrence of a WHO III° oligodendroglioma (MGMT−, IDH1−), originally catego-
rised as treatment-related effect. Both TBRmax (TBRmax = 2.57) and ADCmean (ADCmean = 1815) suggested 
recurrence. A follow-up examination (after 3 months) suggested tumour progression (with midline shift), which 
was later histologically proven in surgery (4 months after hybrid PET/MRI). Fourth row (see Fig. 6, panel δ) 
presents a patient with WHO III° oligodendroglioma (MGMT−, IDH1+, LOH1p/19q+), which was classified 
Figure 2. Bar graph diagrams comparing quantitative imaging parameters from FET PET and DWI between 
recurrent glioma (REC) and treatment-related effects (PTRE) groups. First panel (a) shows FET PET parameters 
(SUVmax, SUV80mean and SUV-BG). Second panel (b) demonstrates DWI parameters (ADCmean, ADC-BG) 
showing a statistically significant difference between recurrence and treatment-related changes with regard 
to ADCmean (p = 0.003). No significant differences between background values were apparent. Last panel 
shows relative imaging parameters for both modalities (rADCmean, TBRmax and TBR80mean). Statistically 
significant differences for rADCmean (p = 0.008), TBR80mean (p = 0.02) and TBRmax (p = 0.02) were found. 
Independent samples t-test, p-value < 0.05 was considered statistically significant. M ± SE.
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as post-treatment related effect. While TBRmax was below the clinically established threshold (TBRmax = 1.73), 
ADCmean (ADCmean = 1362) indicated recurrence. Follow-up MRI examinations (after 3.5 and 6 months) sug-
gested relapse with progressive contrast enhancement, which eventually led to surgery (7 months after hybrid 
PET/MRI) confirming recurrent glioma.
Discussion
In the current study, we demonstrated that the mean apparent diffusion coefficient (ADCmean) in the metaboli-
cally most active regions was higher in patients with recurrent glioma than in patients with post-treatment related 
effects. Both DWI and FET PET facilitated reliable differentiation between glioma recurrence and post-treatment 
related effects. Furthermore, we showed that mean apparent diffusion coefficient (ADCmean) was valuable, 
where maximum target-to-background (TBRmax) ratio remained inconclusive. Thus, highest accuracy (90%) 
was achieved when both DWI- and 18F-FET-derived parameters were combined in a biparametric approach, 
which was superior to evaluating maximum target-to-background (TBRmax) ratio or mean apparent diffusion 
coefficient (ADCmean) alone. When compared to conventional clinical assessment, both false negative (−6%) 
and false positive (−16%) classification rates were improved by biparametric analysis, which results in earlier 
detection of recurrence or avoidance of surgery.
Figure 3. Receiver Operating Characteristic (ROC) analysis. ROC curves for TBRmax (a), ADCmean (b) and 
biparametric analysis of DWI- and FET PET-derived parameters (c, ADCmean and TBRmax) were illustrated. 
Biparametric analysis (c) presented highest AUC (Area Under the Curve). Last panel (d) shows a comparison 





ADCmean + TBRmax 97%/60% 71%/95% 0.90
ADCmean > 1254 62%/100% 100%/72% 0.82
TBRmax > 2 81%/60% 67%/76% 0.81
Clinical rating 91%/44% 62%/83% —
Table 1. Diagnostic measures of clinical assessment and quantitative PET/MRI analysis. Biparametric analysis 
using DWI- and FET PET-derived parameters presents improved diagnostic measures compared to clinical 
assessment.
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While reports regarding the application of quantitative DWI-derived parameters for the differentiation 
between recurrence and treatment-related effects in glioma patients are inconsistent2,7, our results showed that 
glioma relapse presents higher mean apparent diffusion coefficient (ADCmean) compared to treatment-related 
effects, presumably due to tumour necrosis in the centre of solid tumours. While this finding is in accordance 
with some earlier reports14,15, a larger share of previous studies reported that treatment-related effects show higher 
apparent diffusion coefficient (ADC) values than recurrent glioma2.
In these studies, the presumed mechanism for lower ADC values in glioma relapse is higher cellularity due to 
rapid cell proliferation, resulting in relatively impaired diffusivity. This observation is in accordance with indi-
vidual cases in our study, showing recurrent glioma with lower ADC values (ADCmean < 900), likely reflecting 
high tumour cellularity in regions with high tracer uptake, which is in contrast to the larger share of patients in 
this study, presenting increased ADC in recurrent glioma. In a study by Berro et al.16, no link was found between 
increased 18F-fluoro-L-thymidine (FLT) uptake as a marker for cellular proliferation and decreased ADC in pre-
operative glioblastoma multiforme (GBM). 
The current study expands knowledge on tumour metabolism and concurrent diffusivity, showing that the 
metabolically most active tumour sites, where glucose and amino acid uptake are known to be deregulated17, 
present increased ADC values. We assume that the underlying mechanism for increased diffusivity in regions 
with high metabolic activity is tumour necrosis in close proximity to areas with high growth rates, where tumour 
cells eventually become hypoxic and glucose-depleted due to insufficient oxygen and nutrient supply, resulting in 
tumour cell death17. A similar finding was reported by Gadda et al.14, which determined increased ADC values 
for high-grade glioma (HGG) in areas with lactate and lipid compounds as markers for necrosis and hypoxia 
using magnetic resonance spectroscopy (MRS) and conventional MRI. Discrepancies observed between studies 
are likely attributable to methodological and technical differences (e.g. manual lesion segmentation, delineation 
based on contrast-enhancement, perilesional measurements, or less representative 2D-ROIs) in contrast to the 
current study’s rationale of measuring ADC values exclusively in regions with highest tracer uptake.
Figure 4. Additional value of diffusion weighted imaging (DWI) for differentiation between recurrent glioma 
(REC) and treatment-related effects (PTRE). Semi-automated delineation (IC80) of lesion VOI based on PET 
(a) was transferred to the respective ADC map (b). The following panels show post-contrast T1W (c) and a 
3D lesion model (d) for illustration. Each row (α, β, γ) shows a patient with recurrent glioma. While TBRmax 
was at the border of the clinically established threshold (TBRmax > 2), ADCmean values were above threshold 
(ADCmean > 1254) suggesting recurrence.
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While mean apparent diffusion coefficient (ADCmean) was elevated in most patients with recurrent glioma, 
few individual cases showed high diffusion restriction, therefore, suggesting that recurrence should also be con-
sidered at lower levels (ADCmean < 900) in regions with particularly high metabolic activity (TBRmax > 2). 
Moreover, our findings suggest that there is no direct benefit in computing the relative apparent diffusion coeffi-
cient (rADCmean) in contrast to the clinically established target-to-background (TBR) ratio for FET PET, which 
provided additional informative value.
An earlier study from Jena et al.18 indicated that multiparametric imaging using a combination of FET 
PET, dynamic susceptibility contrast (DSC) and magnetic resonance spectroscopy (MRS) may achieve a max-
imum AUC of 0.94 based on logistic regression (n = 26, PTRE/recurrence, 7/19, histopathological/imaging 
follow-up, 9/17). However, lesions were manually delineated based on contrast enhancement and/or FET tracer 
uptake and no practical implementation of multiparametric assessment was provided.
To date, several methodological approaches for the discrimination between glioma relapse and 
treatment-related changes were proposed, such as the evaluation of structural criteria2, qualitative assessment 
of T1-/T2-mismatch19, defined as the contrast-enhanced lesion on a T1W image without matching lesion in a 
T2W image, or quantitative evaluation of the lesion quotient (LQ)20, which is the ratio of lesion size in a T2W 
image and its corresponding size on a T1W image. However, in previous studies, some of these qualitative and 
semi-quantitative methods were shown to yield inconsistent results21,22.
In recent years, it was shown that FET PET is a valuable imaging method for the diagnosis and staging of 
primary brain tumours and pre-therapeutic planning7. The current study demonstrated that simultaneous bipar-
ametric FET PET/MR-imaging is a useful diagnostic approach for the differentiation between recurrent glioma 
and treatment-related changes, which benefits from the integration and combination of structural, metabolic, and 
functional imaging as well as the high spatial and temporal conformance.
Limitations of the current study are a heterogeneous patient collective, restricted sample size, retrospec-
tive study design as well as semi-automated lesion segmentation. A comparison of the current study’s results to 
the existing literature is limited due to the differences in methodology, as discussed above. Moreover, it should 
be taken into account that our findings might not apply to low malignant and slow-growing brain tumours, 
considering the predominance of high-grade glioma in this study. In contrast to manual delineation, which is 
Figure 5. Glioma recurrence with restricted diffusion. Semi-automated delineation (IC80) of lesion VOI based 
on PET (a) was transferred to the respective ADC map (b). The following panels show post-contrast T1W (c) 
and a 3D lesion model (d) for illustration. Each row (α, β, γ) shows a patient with recurrence. While TBRmax 
is above the clinically established threshold (TBRmax > 2) suggesting recurrence, ADCmean shows lower 
readings (ADCmean < 900) indicating diffusion restriction due to high tumour cellularity.
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subject to intra- and inter-rater variation, semi-automated segmentation using isocontours, where thresholds 
commonly vary between 40–90%23,24, presents a more objective and robust approach, despite not being (entirely) 
operator-independent. With regard to the mean apparent diffusion coefficient (ADCmean), where the thresh-
old for differentiation was determined from the current patient collective, optimistic performance estimates are 
possible. Therefore, future studies should investigate and validate simultaneous bi- and multiparametric PET/
MR-imaging in prospective multicentric trials. Further research should explore the potential of fully automated 
feature extraction and radiomics for identification of novel imaging biomarkers as well as radiogenomics for the 
exploration of correlations between imaging phenotypes and genomics.
In conclusion, biparametric analysis using DWI and FET PET in hybrid PET/MR-imaging, both providing 
distinct information regarding the underlying physiology, presented best diagnostic accuracy and clinical benefit 
in differentiating recurrent glioma from treatment-related effects.
Data Availability
Authors confirm that all relevant data are included in the article.
Figure 6. Benefit of biparametric analysis of DWI- and FET PET-derived parameters compared to conventional 
clinical evaluation. Semi-automated delineation (IC80) of lesion VOI based on PET (a) was transferred to 
the respective ADC map (b). The following panels show post-contrast T1W (c) and a 3D lesion model (d) for 
illustration. Labels on the most right show conventional clinical assessment. First row (α) shows a patient with 
PTRE, which was originally classified as glioma recurrence, which led to surgical intervention. Second row (β) 
shows a case with an inconclusive clinical evaluation, which was later shown to be glioma relapse. The following 
rows (γ, δ) present patients with relapse according to histopathology, originally classified as treatment-related 
changes. Clinical assessment would have benefitted from biparametric analysis using TBRmax (TBRmax > 2) 
and ADCmean (ADCmean > 1254), reducing clinical false positive and negative classification.
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